386 filings
Page 9 of 20
8-K
zh2j4 f2hfkz
28 Mar 17
Other Events
12:00am
8-K
5p5rb25k
13 Mar 17
Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options
12:00am
8-K
apy goula
6 Mar 17
Regulation FD Disclosure
12:00am
POS AM
fjhsff4g
2 Mar 17
Prospectus update (post-effective amendment)
12:00am
8-K
1dy03
28 Feb 17
Cempra Provides Corporate Update and Reports Fourth
12:00am
POSASR
zewde7kw1jlh s1x
27 Feb 17
Automatic shelf registration (post-effective amendment)
12:00am
8-K
bhqrncxrs
24 Feb 17
Cempra’s Fusidic Acid Achieves Primary Endpoint In Phase 3 Study of Absssi
12:00am
8-K
7mkyrxuqloc
9 Jan 17
Regulation FD Disclosure
12:00am
8-K
7sha bnjzmq7nj29sw
29 Dec 16
CEMPRA RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR SOLITHROMYCIN NDAs
12:00am
8-K
anzayvrl9dlu up
12 Dec 16
Cempra Appoints DR. David Zaccardelli As Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
12:00am
8-K
qjytkjp773a66
5 Dec 16
Begins Phase 3 Studies In Japan with Cempra’s Solithromycin
12:00am
8-K
0dtzg3y8everou
15 Nov 16
Regulation FD Disclosure
12:00am
8-K
tanurp
10 Nov 16
Other Events
12:00am
8-K
my4y m8nj0pi9
7 Nov 16
Fda Advisory Committee Votes That Efficacy Results of
12:00am
8-K
88ac5d4gl
1 Nov 16
Cempra Receives $10 Million Milestone Payment from
12:00am
8-K
u1uf1yna f3qacy9xbw
27 Oct 16
Cempra Reports Third Quarter 2016 Financial Results and Provides
12:00am
8-K
wc4sfykr517iyo25d
30 Sep 16
Interim Results from Phase 2 Study
12:00am